Search
Flizasertib
go.drugbank.com/drugs/DB21613InvestigationalFlizasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor. … Flizasertib is under investigation in clinical trial NCT06602453 (A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse
Aftobetin
go.drugbank.com/drugs/DB20425InvestigationalAftobetin is a small molecule drug. … Aftobetin is under investigation in clinical trial NCT02928211 (Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations).
Riselcaftor
go.drugbank.com/drugs/DB21685ExperimentalThe usage of the INN stem '-caftor' in the name indicates that Riselcaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and amplifier. … Riselcaftor is a small molecule drug.
Norfloxacin succinil
go.drugbank.com/drugs/DB20858ExperimentalNorfloxacin succinil is a small molecule drug. The usage of the INN stem '-nil' in the name indicates that Norfloxacin succinil is a benzodiazepine receptor antagonist/agonist. … The usage of the INN stem '-oxacin' in the name indicates that Norfloxacin succinil is a nalidixic acid derivative antibacterial. Norfloxacin succinil has a monoisotopic molecular weight of 419.15 Da.
Lisavanbulin
go.drugbank.com/drugs/DB15224InvestigationalLisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Giripladib
go.drugbank.com/drugs/DB15426InvestigationalGiripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Tifcemalimab
go.drugbank.com/drugs/DB18914InvestigationalLung Cancer (LS-SCLC)). … Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell